Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
biotech
2
×
boston
boston blog main
boston top stories
clinical trials
fda
hereditary transthyretin amyloidosis
life sciences
national blog main
national top stories
patisiran
2
×
rna interference
akcea therapeutics
alexion pharmaceuticals
barry greene
boehringer ingelheim
boston university
dan ollendorf
deals
dicerna pharamceuticals
drugs
hepatitis b
hepatitis b virus
inotersen
john berk
mary o'donnell
new york blog main
new york top stories
regeneron pharmaceuticals
roche
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
tafamidis
the amyloidosis foundation
the institute for clinical and economic review
vyndaqel
world health organization
What
ago
alnylam
approve
awaits
biological
caught
causing
crossed
decades
decision
dicerna
discovered
disease
drug
eye
fda
fingers
friday
gene
hepatitis
historic
intended
medicine
medicines
patients
pay
pharma
pharmaceuticals
producing
protein
research
rna
roche
stop
team
time
trick
uses
Language
unset
Current search:
patisiran
×
biotech
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
